Merck to acquire life science company Mirus Bio for US$ 600 million
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
2024 full-year revenue guidance raised by US$ 2 billion
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Subscribe To Our Newsletter & Stay Updated